OptimizeRx Co. (NASDAQ:OPRX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

OptimizeRx Co. (NASDAQ:OPRX) has been assigned a consensus recommendation of “Moderate Buy” from the seven analysts that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $10.42.

A number of research analysts recently issued reports on the stock. William Blair reissued an “outperform” rating on shares of OptimizeRx in a research note on Thursday, November 14th. Barclays decreased their price target on OptimizeRx from $11.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Thursday, November 14th. Stifel Nicolaus lowered their price target on OptimizeRx from $13.00 to $8.00 and set a “buy” rating for the company in a report on Thursday, November 14th. Royal Bank of Canada reduced their price objective on OptimizeRx from $14.00 to $7.00 and set an “outperform” rating on the stock in a research note on Thursday, November 14th. Finally, Roth Mkm reissued a “buy” rating and set a $16.00 target price (down previously from $20.00) on shares of OptimizeRx in a research note on Thursday, November 14th.

OptimizeRx Trading Up 4.1 %

Shares of OptimizeRx stock opened at $5.36 on Monday. The firm’s 50-day moving average price is $5.80 and its two-hundred day moving average price is $8.28. The company has a market capitalization of $98.73 million, a price-to-earnings ratio of -4.03 and a beta of 1.34. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 0.29. OptimizeRx has a 12-month low of $3.78 and a 12-month high of $16.65.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Summit Securities Group LLC bought a new stake in OptimizeRx during the 2nd quarter worth approximately $25,000. BNP Paribas Financial Markets grew its stake in shares of OptimizeRx by 189.2% in the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock worth $28,000 after purchasing an additional 2,414 shares during the last quarter. Quest Partners LLC increased its holdings in OptimizeRx by 15,965.6% in the third quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock valued at $76,000 after purchasing an additional 9,739 shares during the period. Connors Investor Services Inc. increased its holdings in OptimizeRx by 15.1% in the second quarter. Connors Investor Services Inc. now owns 19,107 shares of the company’s stock valued at $191,000 after purchasing an additional 2,500 shares during the period. Finally, Barclays PLC raised its position in OptimizeRx by 358.5% during the 3rd quarter. Barclays PLC now owns 26,934 shares of the company’s stock worth $208,000 after purchasing an additional 21,060 shares during the last quarter. Institutional investors own 76.47% of the company’s stock.

About OptimizeRx

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.